Meeting
2023 ASCO Annual Meeting
Blinded-assessment of a solution to evaluate olaparib maintenance treatment efficacy in patients with ovarian cancer from the GINECO/ENGOT PAOLA-1 trial.
Authors
Adrien Buisson
Department of Biopathology, Centre Léon BERARD, Lyon, France
Adrien Buisson , Pierre Saintigny , Pantelis Constantoulakis , Katerina Oikonomaki , Stavroula Samara , Philipp Harter , Sandro Pignata , Antonio Gonzalez Martin , Christian Schauer , Keiichi Fujiwara , Ignace Vergote , Nicoletta Colombo , Eric Pujade-Lauraine , Isabelle Treilleux , Isabelle Laure Ray-Coquard
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5588)
DOI
10.1200/JCO.2023.41.16_suppl.5588
Abstract #
5588
Poster Bd #
283
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy of subsequent therapies in patients (pts) with advanced ovarian cancer (AOC) in the phase III PAOLA-1/ENGOT-ov25 trial according to whether disease progression occurred during or after the end of olaparib (ola) maintenance.
First Author: Philipp Harter
First Author: Emmanouil S. Saloustros
Poster
2023 ASCO Annual Meeting
Systematic high-throughput combination drug screen to enhance poly (ADP-ribose) polymerase (PARP) inhibitor efficacy in ovarian cancer.
First Author: Katherine Foster
Poster
2023 ASCO Annual Meeting
BRCA1 and RAD51 methylation impact on outcome in patients with advanced ovarian cancer: A PAOLA-1 ancillary study.
First Author: Helene Blons